瑞士巴塞尔大区经济及创新促进局欢迎您

在瑞士最具活力的经济地区培育创新,加速业务发展  >>>>

最瑞士

瑞士是亲商、可靠和高效的代表。巴塞尔地区经济强盛,秉承明确的亲商核心价值,是瑞士这些美德的光辉榜样。  >>>>

生命科学和医疗行业第一

整个生命科学价值链汇聚于一处,且触手可及?这是600家及越来越多的公司对巴塞尔地区情有独钟,将其作为研发、生产和总部的原因。  >>>>

创新行业第一

多项研究结果表明,瑞士是全球最具创新精神的国家。巴塞尔地区丰富的知识、高素质国际人才和强有力的产业支柱使瑞士成为领先的创新枢纽。  >>>>

往来欧洲交通便利度第一

无论是集装箱运输还是空运,巴塞尔地区都拥有交通便利的优势。它与德国和法国接壤,位于欧洲中部的中心地带,是国际贸易青睐的物流枢纽和城市平台。  >>>>

文化和休闲第一

世界级艺术珍宝、文化和体育活动,融入健康自然娱乐景观中的国际化都市氛围,所有这些因素结合在一起,使巴塞尔地区成为全球最适宜居住和工作的地区之一。  >>>>

瑞士巴塞尔大区经济及创新促进局是瑞士西北地区巴塞尔乡村州、巴塞尔城市州和汝拉州为促进创新和经济发展而联合成立的机构。本机构旨在帮助国外企业家和公司在巴塞尔地区成功实践创新,创立公司。

我们拥有15,000名决策者、创新者、专家、影响者和增值者组成的广泛关系网络,让客户能直接获取相关专业知识和技术。

瑞士巴塞尔大区经济及创新促进局主要在以下四个领域内为客户提供定制化服务:

投资巴塞尔地区

提供个性化支持,帮助客户在巴塞尔地区择址。本机构将在整个择址和入驻过程中为公司提供中肯的建议。

为创新着牵线搭桥

帮助生命科学、医疗技术、信息通信技术(ICT)、微技术、纳米及材料和生产技术领域的公司和研究人员在技术、研发和创新事务方面建立联系。

支持创业

为计划在巴塞尔创业的企业家提供全面支持,在其商业计划的运营执行过程中进行协助。此外,以上技术领域中处于扩张模式的初创公司和中小型公司可从策略性交流服务中受益,与行业专家和投资人建立联系。

进驻中国

为瑞士西北部地区寻求扩张到中国的公司提供适当的合作伙伴网络,协助其顺利进驻中国市场,执行扩张项目。

瑞士巴塞尔大区经济及创新促进局还管理着一个综合性信息平台,展示巴塞尔商业地区的优势和专长领域,进一步促进该区域创新公司的融入:

创新报告

涵盖巴塞尔地区最新创意活动和报告,每月发布一次新闻简报,内容包含采访、背景故事和公司入驻本地的消息。

创新活动

瑞士巴塞尔大区经济及创新促进局每年组织并合办逾50次专门针对知识转移和创业文化的活动。在“创新活动”中,创新者和企业家分享他们最新的创新理念和经验。

在竞争力和创新能力方面,瑞士已多年位居世界顶级营商目的地前列。多个因素保证了瑞士的领先地位。除了优良的教育和先进的基础设施外,让瑞士等同于亲商、可靠和高效的另一个重要原因就是高效的瑞士政府机构。几十年来,瑞士强有力的法律系统、可靠的规划和稳定的金融体系使得在瑞士经营的公司及其在这里的投资项目都受益匪浅。这种环境也是企业向新市场持续扩张的一个最重要的前提条件。瑞士跨国公司密度全球最高绝非偶然。

巴塞尔地区对瑞士的成功做出了重大贡献。众多国际领先跨国公司不仅发迹于此,这些公司的成功也为该地区的经济增长注入强劲动力。例如,巴塞尔地区的GDP远高于瑞士全国平均水平。大巴塞尔地区人均国内生产总值为瑞士最高。与此同时,巴塞尔在生命科学和其他高科技领域的领先优势推动了瑞士创新能力的发展。例如,瑞士约有占总值五分之一的出口货物在巴塞尔地区制造,考虑到巴塞尔地区人口仅占瑞士人口不到10%,这是十分了不起的成就。

在全球商业、产业和知识竞争力方面,瑞士,特别是巴塞尔地区享有的美誉主要体现在以下四个突出优势上:

明智的税收政策

瑞士采用的联邦制度鼓励州与州之间的财政竞争,使税收保持在合理的范围内。除了联邦层面的统一税率外,各州可自主确定税率,并为公司提供最佳的营商环境。由此,巴塞尔地区的主要受益人是活跃在创新行业、具有高附加值的公司,以及大力投资研发和生产的公司。

自由的劳力市场

由于巴塞尔地区拥有众多活跃于国际的高科技公司,地方政府对于他们对海外高素质专家和高级管理人员的需求采取支持态度。这一欧洲最自由的劳动市场之一使得企业从中受益,同时也给予员工巨大利益。巴塞尔地区的劳动法规和劳力市场使得公司可以在营商环境发生变化并需采取相应措施时能够做出快速反应。

可持续的基础设施

在瑞士,火车晚点5分钟就会令人不快,但这种情况极少发生。这一点常令外国访客露出满意的笑容。众所周知,瑞士的公共基础设施堪称世界上最先进、最可靠的,而巴塞尔地区的优势正在于此。交通四通八达,通过公路、铁路和飞机航线可往返欧洲各地,通过莱茵河的水路可通向全球。

双轨制教育体系

瑞士仅三分之一的年轻人高中毕业后选择继续在瑞士顶尖大学深造。对于很多国家来说,这也许是教育体系的重大失职。但是实际上,这是瑞士在专业技术上成功的一部分原因。瑞士双轨制教育体系旨在确保大多数年轻人完成瑞士联邦认证的学徒期,以尽早参加工作。年轻人可以(也通常会)在瑞士技术学院或应用科学类大学获取专业学位,大多是在职学位。这为瑞士劳力市场稳定提供了经过多年在职培训的入门级雇员,这些人员可以在最具发展潜力的行业进行灵活就业,而雇主和行业实际上也需要这样的人才。此外巴塞尔地区的独特优势在于其拥有众多完善的国际学校,这些学校能够满足外籍人士及其子女的需求,帮助他们轻松融入当地。

作为唯一一个基于直接民主制的政治体系,瑞士在几百年里建立起独特的具有凝聚力的政治和社会文化。其特点是联邦制、自治和一致性,是稳定的政治和社会环境的基石,也是瑞士价值观的体现。巴塞尔地区政府及其民众的开放思想和进取态度,使其成为营商目的地的典范,为企业提供了优良的发展环境,推动企业不断发展壮大。

巴塞尔地区是生命科学领域全球最受欢迎的目的地之一,在欧洲更是无出其右。作为全球市场前三强的罗氏和诺华都是从巴塞尔地区起家,继而将业务拓展至全球。

与之类似的其他跨国公司也在巴塞尔建立了其中心业务分部,其中包括礼来、雅培和拜耳。Actelion、Basilea和Evolva等众多新入驻的公司以及Bachem和Polyphor这样高度专业化的公司使得巴塞尔形成完整的生命科学生态系统。并不令人意外的是,巴塞尔地区还演变成具有发展前景的初创公司钟爱的热点地区。

巴塞尔地区有共计700家生命科学公司,它们对该地区业已颇具活力的营商环境做出重大贡献。这些企业的持续成功主要基于以下三个因素:

生命科学行业是巴塞尔地区经济增长的引擎。这个行业在此生根发芽,且枝繁叶茂

巴塞尔地区生命科学行业的雇员共计3.3万名,每小时生产的产品和服务价值高达3.21亿美元。这使巴塞尔地区成为全球生产力最高的生命科学目的地。巴塞尔地区的生产总值也位居全球之冠:巴塞尔地区的产量全球最高,年产值达190亿美元。与此同时,巴塞尔地区每年获得60亿美元研发投资,是全球这方面数额最高的地区。本地生命科学使经济增长高于瑞士全国平均水平,这使得该行业在巴塞尔地区的声誉无可挑剔。

巴塞尔地区拥有各类人才和专家,而且人数众多

从研发、创办公司到制造、营销和分销,巴塞尔地区拥有一条完整的生命科学价值链,因此您能找到企业在各个发展阶段和各个职能所需的人才和专家。他们人数众多,且经验丰富。加上顶尖的研究机构,如巴塞尔大学生物研究中心(Biozentrum)、苏黎世联邦理工学院(ETHZ)生物系统科学与工程学院和弗雷德里希•米歇尔研究所(FMI),您大致可以了解到巴塞尔地区独特的生命科学资源组合的范围有多广。该地区有触手可及的资源、技术和人才,其深度和密度在全球范围都无可匹敌。这为未来创新提供了独一无二的肥沃土壤。

巴塞尔地区作为生命科学行业的创新标杆已有逾250年的历史

因此巴塞尔地区可谓是涉足生命科学领域历史最悠久的地区。从十九世纪中叶的工业丝带染坊到生物技术革命,巴塞尔的生命科学生态系统不断演进,并在行业的巨大发展中实现了自身突破。这一光辉故事将被续写。与其他曾经实现发展的生命科学中心不同的是,巴塞尔地区在过去几年一直保持稳定和持续的增长。该地区未来几年计划在公共和私人基础设施项目上将投入60亿瑞士法郎,因此下一个高增长期指日可待。

传统优势、强有力的产业支柱、深厚的研发和商业化专长,使得巴塞尔地区成为全球最为完善和成熟的生命科学目的地。您很难再找到另一个像巴塞尔这样适合在生命科学领域高效、可持续和成功地开发科研及商业项目的地区。

高科技是巴塞尔地区经济的推动力,并且是本地经济增长高于平均水平的保障。而且这种局势将持续下去。强有力的产业支柱、吸引全球人才和专家的国际化营商环境,加上瑞士世界一流的教育体系,使巴塞尔地区成为创新的理想环境。在这里,企业,尤其是医疗技术、信息与通信技术、精密机械以及化工业公司都将从该地区的以下特点中受益:                       

巴塞尔地区拥有深厚的高科技产业基础

巴塞尔城市州92%的产业附加值来自高科技公司。类似地,在巴塞尔乡村州和汝拉州,该比例远高于70%,因此高于瑞士60%的平均水平。而瑞士60%的平均水平已使其跻身于世界最具创新精神的国家之列。

巴塞尔地区是研发领域领头羊

瑞士私营部门的研发投资比例高达69%,在全球范围内都属于较高比重。其中40%来自巴塞尔地区,而本地人口仅占瑞士人口的10%。瑞士国内专利最多的十家公司中有五家的总部位于巴塞尔地区,它们是罗氏、诺华、科莱恩、先正达和Endress+Hauser。这也是为什么巴塞尔地区成为瑞士国内聘请研发人员最多的地区。

巴塞尔地区与全球紧密联系,吸引着世界各地的人才

巴塞尔70万居民中约有五分之一来自海外;当前外籍人士达到3.6万人。巴塞尔地区与德法两国接壤,每天有7万名跨境上班族从邻国流入。很难再找到一个地区,像巴塞尔地区这样在如此小的区域内拥有如此具有活力的国际商务氛围,并吸引着全球各地的专业人才汇聚一处。

世界一流的科学和学术教育

除了是强大的产业研发中心外,巴塞尔地区在欧洲学术界举足轻重。巴塞尔大学拥有2,000名教授和1.2万名学生,是欧洲历史最悠久的大学之一,位居全球100所大学之列。从巴塞尔地区乘火车,2小时内即可到达苏黎世联邦理工学院(ETHZ,在巴塞尔设有生命科学学院)和洛桑理工学院(EPFL)。这两所大学都是全球绝对一流的大学。巴塞尔地区(包括其交界国)数百公里范围内共有167家研究机构。此外,瑞士的双轨制教育体系和瑞士西北应用科学大学稳定提供训练有素的高技能专业人才。

研究和调查结果显示,瑞士多年来一直都是全球领先的创新地区之一。强有力的产业支柱、吸引全球人才的全面国际化营商环境,再加上瑞士学术和双轨教育体系,使巴塞尔成为瑞士的创新枢纽。巴塞尔地区的资源密度可谓独一无二:在巴塞尔地区,最高水平的科学表现、行业专长和技术,以及高素质的劳动力都触手可及。


早在罗马帝国时期,巴塞尔莱茵港口就是通向北海航道的最南端港口。1226年,博登湖和北海之间的莱茵河段上建成第一座桥梁(也是此后多年唯一一座),使得巴塞尔演变为重要的贸易枢纽。巴塞尔地区与德国和法国接壤,位于欧洲中部的中心地带,保持了其作为瑞士最重要交通和物流枢纽的领先地位,为本地产业和商业带来诸多利益。
此外,巴塞尔地区特别适合计划在欧洲建立全球总部,以及积极追求全球贸易新机遇的公司。巴塞尔地区具有以下独特优势:

巴塞尔地区是欧洲重要的交通枢纽

从市中心乘出租车或公交仅需15分钟即可到达巴塞尔机场。从该机场可到达欧洲、北美和中东的90多个目的地。集装箱从巴塞尔城的三个莱茵河港口发出,三天内可到达鹿特丹港,而后从那里运往全球各地。火车站每个小时就有一列开往瑞士所有主要城市的火车,如苏黎世(包括苏黎世国际机场)、伯尔尼、洛桑和日内瓦,以及莱茵河畔的各个经济中心(即弗莱堡、卡尔斯鲁厄和斯特拉斯堡)。乘坐高铁几个小时就可轻松便捷地到达欧洲各大都市和首都,如法兰克福、巴黎和米兰。

巴塞尔地区是瑞士领先的物流枢纽

巴塞尔的三个莱茵河港口吞吐量占瑞士外贸总量的12%,其中食品和农产品吞吐量高达84.2万吨。整个巴塞尔地区的外贸额占瑞士总量的三分之一。巴塞尔机场是瑞士领先的货运机场。这使得巴塞尔作为物流枢纽的地位名副其实。巴塞尔物流行业拥有2.3万名从业人员。990家物流公司落户巴塞尔地区,包括市场领导者DHL、Panalpina、Goldrand 和嘉里物流。这些公司可提供成熟的解决方案应对复杂挑战,例如在供应链管理方面,而这正是生命科学和化工业企业常常需要的。

巴塞尔地处欧洲中心位置,是国际贸易公司的理想之选

特种烟草制造商大卫杜夫、零售商Dufry、餐饮公司 Transgourmet 和国际清算银行等各类公司和机构凸显出在巴塞尔交易和提供的货品的多样性。因此瑞士第二大连锁超市Coop和第一大百货公司Manor都选择将总部设在巴塞尔地区。该地区同样是一系列国际贸易展会的重要举办地。每年举办的巴塞尔国际钟表珠宝展(BaselWorld)实现了国际名表和珠宝业的很大一部分销售额。而巴塞尔艺术博览会(Art Basel)则是全球最重要的艺术盛会。越来越多的国际消费品牌已发现巴塞尔作为贸易枢纽的优势,并将欧洲总部设在巴塞尔地区。其中就有美国著名时尚品牌Fossil、自行车制造商Cannondale和时装设计品牌Tally Weijl。

越来越多的跨国公司发现将巴塞尔作为其全球或欧洲总部的吸引力,特别是考虑到巴塞尔出色的连通性和运输系统以及本地在物流和国际贸易上的优势。老字号瑞士公司和初创公司都在利用这里处于欧洲中心所带来的优势。最后,巴塞尔地区毗邻德国和法国,与世界各地交流频繁,本地人口具有世界性,使得整个商业区域生机勃勃,持续增长。

早餐在德国,中餐在法国,晚餐在瑞士:巴塞尔地区地处三国交界处,具备都市化的国际商业氛围,与瑞士其他都市地区相比,人们可以以相对较低的成本享受无与伦比的生活品质。获奖建筑、历史悠久的市中心和从嬉皮士到经典风格的丰富精致的文化生活,都是巴塞尔地区良好城市生活方式的几大支柱。同时,成熟的公共交通系统可快速直达郊区和乡村居住区,以及那里的自然公园和休闲场所。

问一问新来者和新移民:巴塞尔不仅拥有瑞士最大的外籍人士社区,各种国际学校为他们的子女提供教育,而且是定居时间超过5年外籍人士比例最高的地区。原因不止一个:

每个人都能享有巴塞尔的城市生活方式和丰富的文化生活

巴塞尔的根基在罗马和凯尔特人时期就已打下。中世纪末尾至现代初期,该地区首次达到全盛。当然,巴塞尔并未止步于此。现今,巴塞尔繁荣的创意行业、各色当地美味餐馆,以及丰富的文化活动带来了生机勃勃的都市生活方式。在狂欢节时漫步风景如画、历史悠久的市中心,在新巴洛克风格的交响乐厅前停留,或在夏季到明斯特广场观赏户外电影——巴塞尔总是精彩不断。

到了巴塞尔,艺术爱好者就来对了地方

巴塞尔美术馆创立于1671年,被视作历史最悠久的公共社区艺术博物馆。根据伦敦泰晤士报的排名,该馆位列世界5大美术馆之一。另一吸引人的景点是拜尔勒基金会博物馆。该馆由意大利著名建筑师Renzo Piano设计。巴塞尔的另一个艺术重头戏是全球最大的艺术展——巴塞尔艺术博览会(Art Basel)。每年,艺术家、收藏家、画廊和拍卖行以及名流贵宾早早地就在日历里标出博览会举办的日期。他们中有些人会赶来欣赏巴塞尔剧院享誉全球的获奖演出(有歌剧、戏剧和芭蕾舞)。

巴塞尔地区总是充满了运动气息,而且不仅是在体育馆或沙发前的电机上

本地最受欢迎的巴塞尔足球俱乐部(FC Basel)在圣雅各布公园主场迎战欧洲足球顶尖赛事的对手。ATP巡回赛的一流选手参加瑞士室内网球锦标赛,其中包括本地超级球星罗杰·费德勒。在竞技场之外,巴塞尔民众也很热衷于运动。巴塞尔地区自行车使用率为全瑞士最高,包括骑车的上班族和在周边乡间无数自行车道上行进的骑行爱好者。跑步爱好者可在莱茵河两岸的无障碍通道跑步。越野滑雪爱好者可在汝拉州绵延数公里的缓坡上滑行。驱车2小时不到,高山滑雪者和雪板滑雪者就可达到瑞士阿尔卑斯山的原始山坡上。

在瑞士、德国和法国交界处,有各色吸引人的活动等着您

是参加阿尔萨斯的品酒会、巴登-符腾堡南部的美食盛宴,还是在汝拉州山峰上惬意地野餐?在巴塞尔地区,没有一小时车程里满足不了的需求。而且,总会有新发现!想在炎炎夏日跳进沁凉的河水中吗?这时,莱茵河岸线将成为名副其实的地中海里维埃拉——就在巴塞尔市中心。

唾手可及的各色活动、无与伦比的一流公共交通基础设施、安全和稳定的政治局势使得瑞士经常位居生活质量调查排行榜前列。这些都能在巴塞尔地区轻松获得,而艺术文化、生活方式和国际氛围更是锦上添花。因此不足以为奇的是,巴塞尔被瑞士年轻人视作瑞士最具嬉皮士精神和最时尚的地区之一。

我们的服务
Gabriela Güntherodt

您的联系人

Gabriela Güntherodt

Member of the Management Board, Head of International Markets & Promotion

联系我们

投资巴塞尔地区

您的公司正在扩张吗?您正计划立足欧洲和瑞士,借以打入新市场吗?如是,那么巴塞尔地区正是您的理想之选。您将发现让您长久立于不败之地的要素近在咫尺。

众多跨国公司(主要是生命科学领域)确保了真正国际化的商业环境。巴塞尔地区拥有具有国际思维的人才库,整条价值链和各个职能环节都有高技能人才。巴塞尔地处欧洲中部,毗邻法国和德国,因此可以提供良好的商业环境,以及瑞士闻名于世的生活品质。

您想了解在此地区投资的好处吗?我们很乐意为您展示。我们的专家将在贵公司扩张项目的各个阶段为您提出全面而专业的建议。

评估

税务?就业市场?竞争对手?政府许可?产业环境?我们将根据您独特的项目要求,收集巴塞尔地区及瑞士的所有相关信息和数据。

选址

有任何待解决的问题?我们将寻找合适的专家为您答疑解惑。我们会将您介绍给政府机构、行业和法律专家,并在您置业的过程中提供专业支持。

实地考察

您想亲自了解巴塞尔地区吗?我们将完全根据您的需求精心定制一份高效的实地考察计划和行程。

商业开发

您想让公司业务增长提速吗?我们将帮助您建立与本地合作伙伴和机构之间的联系,加快您进驻巴塞尔地区高度多样化商业和创新生态系统的步伐。                                      

我们的服务将免费提供给那些正考虑择址巴塞尔的公司,这也有助于营造充满活力的商业环境。创新和接受新理念的开放心态是巴塞尔地区的悠久传统。我们期待听取您的商业理念,并协助您一开始就取得成功。

Gabriela Güntherodt

您的联系人

Gabriela Güntherodt

Member of the Management Board, Head of International Markets & Promotion

联系我们
Sebastien Meunier

您的联系人

Sebastien Meunier

Member of the Management Board, Head of Innovation & Entrepreneurship


Tel. +41 61 295 50 15

sebastien.notexisting@nodomain.commeunier@baselarea.notexisting@nodomain.comswiss

为创新者牵线搭桥

“为创新者牵线搭桥”服务将创新构想、企业和企业家召集在一起。该服务有两种形式,一种是瑞士巴塞尔大区经济及创新促进局组织的非正式的专家活动,另一种是正式的针对性支持服务,为具体项目提供专家、合作伙伴和融资。我们的专家拥有8000多名创新者组成的强大网络作为后盾。

“为创新者牵线搭桥”服务主要面向以下五大核心主题领域:生命科学、医疗技术、信息与通信技术、生产技术和微技术、纳米技术和材料。每个技术领域都由一名专家专门负责。技术领域经理与行业展开密切合作,制定活动计划,担任项目的联系伙伴,与巴塞尔地区相关研究机构和其他机构培养伙伴关系。

因此,“为创新者牵线搭桥”服务为客户提供了立足于巴塞尔地区、从其多样化创新生态系统受益的理想入口。企业家、创新者和专家每年在逾50场活动上汇聚一堂,定期交流理念和知识,活动形式多种多样:

专题活动:专注于知识转移,为公司、特别是新创公司提供介绍公司和项目的机会,促进巴塞尔地区的创新者进行跨公司和跨学科的经验和知识交流。
研讨会:以拓展新技术应用范围以及发起具体项目和合作企业为目的,通过加强各个公司和学科的专家之间的对话,深度探讨某个主题。
技术与创新圈:运行多年的创新举措,目的是在各个公司和学科所组成的社区中进一步开发主题,以及探索新的市场潜力。

瑞士巴塞尔大区经济及创新促进局的支持创业服务为处于初创阶段的企业提供针对性的活动和服务。

Sebastien Meunier

您的联系人

Sebastien Meunier

Member of the Management Board, Head of Innovation & Entrepreneurship


Tel. +41 61 295 50 15

sebastien.notexisting@nodomain.commeunier@baselarea.notexisting@nodomain.comswiss
Sebastien Meunier

您的联系人

Sebastien Meunier

Member of the Management Board, Head of Innovation & Entrepreneurship

联系我们

支持创业

您正计划创业?这太好了,因为巴塞尔地区以创业为生。瑞士巴塞尔大区经济及创新促进局作为巴塞尔地区创新和外来投资的推进机构,为技术和创新领域的企业家提供支持。

我们服务的核心内容是研讨会及工作坊项目:

  • 创始人课程:扶持性服务的核心内容是我们的研讨会及工作坊项目。“创始人课程”基本套餐的目标群体是计划创业的所有意向方。可在此浏览其他课程的概述:课程概述

    更多服务是专门针对在创新和科技领域有具体项目的初创公司和企业家:
     
  • 企业家研讨会及工作坊:在这些活动中,可以就各种商业问题,例如商业计划、融资、产品开发、定价和知识产权,以及营销与沟通进行深入探讨。这一系列活动专门针对有具体创新项目的初创公司和高科技中小型企业。

    除了培训课程和研讨会之外,瑞士巴塞尔大区经济及创新促进局还提供针对具体项目的单独咨询服务。该咨询服务专门针对创新和科技领域增长潜力巨大的公司和项目。
     
  • 联系与咨询:在初期咨询中,我们的专家将评估对支持的需求,并与专业人士、研究机构或潜在合作伙伴建立联系。
  • 新企业评估:在有专人指导下的流程和单独召开的专家会议中,初创公司和创新型中小企业可以请知名的行业专家、企业家和投资人对其商业项目进行评审。更多信息

    瑞士巴塞尔大区经济及创新促进局的服务涵盖创业的初期阶段。目标是在初期构想到实际创业,再到首个实施计划和融资的过程中,提供宝贵信息和切实的建议。这不仅给予企业家更多安全保障,而且可以显著加快他们实施项目的速度。
Sebastien Meunier

您的联系人

Sebastien Meunier

Member of the Management Board, Head of Innovation & Entrepreneurship

联系我们
Gabriel Schweizer

您的联系人

Gabriel Schweizer

Senior Project Manager Asia


Tel. +41 61 295 50 13

gabriel.notexisting@nodomain.comschweizer@baselarea.notexisting@nodomain.comswiss

进驻中国市场

过去几年中,中国作为商业市场的重要性不断提升,从最初的低成本消费品生产的海外目的地,逐渐发展成为今天全球主要的销售市场和人才荟萃之地。将业务扩张到中国市场将给予公司巨大的发展潜力,尤其是对于中小型高科技公司而言。但想在中国这样复杂的市场占据一席之地,并非易事。

因此瑞士巴塞尔大区经济及创新促进局为巴塞尔地区(巴塞尔城市州、巴塞尔乡村州和汝拉州)的公司提供全面支持,从初期的市场评估,直至寻找到商业合作伙伴。除了提供必要的专业知识外,我们的顾问还拥有良好的本地人脉,这些都是多年来与政商界往来所积累起来的。瑞士巴塞尔大区经济及创新促进局还构建有一个颇具规模的公司和专家网络,他们有与中国打交道的丰富经验,了解所有最新发展趋势。

作为一年一度的瑞中生命科学论坛的协办单位,瑞士巴塞尔大区经济及创新促进局将助力推进中国与巴塞尔地区之间的交流。

生命科学公司同样能从与上海张江高科技园区和新建的枫林生命科学园区的合作关系中受益,借此打入中国领先的生命科学枢纽。久经考验的中国本地合作伙伴可以提供支持,协助在上海开展业务(包括产品注册、融资、营销等)和与潜在商业合作伙伴及客户建立联系。

Gabriel Schweizer

您的联系人

Gabriel Schweizer

Senior Project Manager Asia


Tel. +41 61 295 50 13

gabriel.notexisting@nodomain.comschweizer@baselarea.notexisting@nodomain.comswiss

我们的渠道: 活动|博客

report BaselArea.swiss

Roivant raised USD 200 million, now valued at USD 7 billion

14.11.2018

The Basel-based pharmaceutical company Roivant Sciences has raised USD 200 million in a funding round. As a result, the company is now valued at an estimated USD 7 billion.

Roivant Sciences reported in a press release that all existing institutional shareholders participated in the latest funding round. The Basel pharma company also attracted a number of new investors, including NovaQuest Capital Management and RTW Investments. These new investors made up the majority of this latest funding drive, in which Roivant raised USD 200 million. The round has not yet finished and is only expected to close in early December. According to the press release, this latest financing puts the value of Roivant Sciences at approximately USD 7 billion.

Since the previous Roivant funding round last year, the number of therapies in development has grown from 14 to 34 and the company has increased its subsidiary “Vants” from six to 14. There has also been growth in employee numbers across Roivant and the Vants, from under 350 to more than 750. In addition, the Roivant subsidiary Enzyvant initiated a biologics licence application for a regenerative therapy to the U.S. Food and Drug Administration (FDA).

For 2019, the company anticipates topline data from six Phase 3 clinical trials. Roivant Health also intends to launch new Vants next year. This subsidiary was founded in June to develop companies that bring innovative medicines to emerging markets and improve the process of developing and commercialising new medicines through the application of technology. Sales are also expected to grow for Datavant, founded in autumn 2017 as a subsidiary that uses artificial intelligence in data analysis to improve the clinical trial process and accelerate drug development.

Roivant Sciences and its subsidiaries are supported by BaselArea.swiss as they establish themselves in Basel.

report Life Sciences

GETEC acquires Infrapark Baselland

20.11.2018

event ICT

Digital Business Lunch: Digital workplace, placer le collaborateur au centre de l’activité

Date: 21.11.2018

Place: Campus Strate J, Route de Moutier 14, 2800 Delémont

report Production Technologies

Three entrepreneurs, three visions of Industry 4.0

05.11.2018

BaselArea.swiss invited startups and Industry 4.0 projects to participate in the first Industry 4.0 Challenge. A jury from the industry chose three finalists: Philippe Kapfer with NextDay.Vision, Roy Chikballapur with MachIQ and Dominik Trost with holo|one. Learn more about their contributions and visions in the interview. You can meet the entrepreneurs at the Salon Industries du Futur Mulhouse on 20 and 21 November 2018.

BaselArea.swiss: Which problem does your company aim to solve?

Dominik Trost, holo|one: In general, our solutions utilise Augmented Reality to quickly bring know-how to where it is needed. This translates to offering intuitive means of maintenance support, such as holographic checklists or reporting tools, as well as AR enhanced remote assistance for companies to provide electronic information to sites around the globe, alongside common audiovisual calls. We also use holograms and animations as storytelling tools, and are developing an app entirely dedicated to design and presentation purposes. Most of all, we believe in keeping things simple: Our apps concentrate on a core set of powerful features and can all be managed through our browser-based management portal. People should be able to use our apps with as little effort as possible.

Roy Chikballapur, MachIQ: We help machine builders and manufacturers to gain equipment and asset performance. To that end, MachIQ provides a software for machine builders to simplify customer support and to monitor their machines, hence reducing unplanned outages for their customers. For manufacturers, MachIQ created a software that helps with predictive support and that combines useful functions for plant managers, controllers and the maintenance team alike. In short: We bring machines to life.

Philippe Kapfer, NextDay.Vision: We simplify communication between machine manufacturers and their customers and makes them safer. Normally, connections between two contacts are insecure and vulnerable because one or even both sides have to open the connection. This makes them vulnerable. Also, you usually need to interrupt the workflow to validate a partner. Our API is designed to help companies create integrated software. For example, a company can update its machine remotely and integrate the validation workflow directly on the customer side. The customer just logs on to his smartphone. He does so by signing in by hand. Afterwards, the manufacturer can update the machine from a distance. This leads to a traceable and rule-compliant process.

When and why did you found your company?

Philippe Kapfer: NextDay.Vision has been around since mid-2017. Before that, I wrote a book on the security of computer systems as part of my master's thesis, showing how Windows can be hacked – corporate computer systems are easily attackable from the inside. For fear of such attacks, many companies do not use the cloud, for example, and try to keep their systems closed. In discussions with machine manufacturers and their customers, I realized that there is a lack of solutions for this. In the course of digitalization, the question naturally arises as to how we can make connections secure. My company provides answers to that question.

Roy Chikballapur: When I was with Schneider Electric in Paris, I helped to digitalize industrial offers for different companies. However, by talking to the machine builders and manufacturers I learned that they struggled with much more basic problems. One of these fundamental problems is customer support – it simply takes too much time to look up customer and serial numbers and to fix stuff. All the while, the machine is not producing anything and only generates losses for the respective company. I had the idea for my company in 2014, in 2016 I launched MachIQ.

Dominik Trost: It all began with the presentation of the Microsoft HoloLens: We saw the presentation live and knew that AR will be a big thing using head-mounted devices. Soon we got the first device and had lots of workshops with companies from different areas of business. We immediately realized the benefits of this technology and companies saw their AR use cases too. After assessing the market potential in Switzerland, we founded our company just at the end of that year, first concentrating on individual showcases. We soon realized that a standardized approach better satisfies corporate needs, but there was still a lot of work to do: This year, we almost exclusively worked on developing ‘sphere’, our new AR platform that will be released at the end of November.

How did you learn about the i4 Challenge and why did you apply?

Dominik Trost: Markus Ettin, industry 4.0 and automatization manager at Bell Food Group, suggested that we might be a good fit for the i4.0 Challenge and motivated us to look deeper into it. Though having an international outlook, we found it important to strengthen the regional awareness for our technology as well, so we took our chances…

Philippe Kapfer: For me, the Challenge was like another litmus test. I wanted to know how our solution was received. In the Industry 4.0 Challenge, I had the opportunity to have my project reconfirmed by industry experts. At the same time, the jury acknowledged that we were actually bringing something new to industry.

Roy Chikballapur: We were in touch with the BaselArea.swiss team thanks to their support in us relocating from the Canton of Vaud to Basel-Stadt. Sebastien Meunier, who was responsible for the initiative posted about the i4 Challenge on LinkedIn and this is how we found out about it. I believe that the discussions on BaselArea’s LinkedIn community are very relevant to what’s happening in the Industry 4.0 sector and this is what motivated us to apply.

What does the term “Industry 4.0” mean to you and why do you consider the topic significant?

Dominik Trost: To us, industry 4.0 is the logical evolution of industry with the tools and technologies that are available or being developed. Like the ‘4.0’ epithet already suggests, we think that it is the industrial revolution of our generation, adding immense amounts of productivity, safety, and interconnectivity. It is therefore obvious to us that industry 4.0 will remain the hot topic over the following decade, and now is the ideal time to get on board.

Philippe Kapfer: I believe that "Industry 4.0" is often used to sell a new product or service. Often the technology was there before and is merely used differently under the title Industry 4.0. For me, that label first and foremost means that the industry is evolving.

Roy Chikballapur: I think there is more to the phrase. I agree that a lot of focus today seems to be on the technologies that enable the digitalization of processes, the generation of useful data and the algorithms that many expect will replace human beings in several functions on the shop floor. At Machiq however, we focus on the business model transformations that these technologies will bring about when they are deployed at scale and we find few companies are preparing themselves for this.

Here is an example: Most machine builders consider the sale of spare parts and the delivery of maintenance and repair services as their “Services Business”. However, their customers are actually buying the experience of zero unplanned outages. With the improved ability to connect machines and to analyze performance data in real time, outages can now be prevented.
However, in doing so, machine builders will likely reduce their spare parts revenue. Are they ready for this? Not as long as they stick to current business models. But what if they offered a “Netflix of spare parts and services”-contract where the customer instead buys uptime.

What if a yoghurt producer could pay his equipment supplier based on the number of pots of yoghurt produced per month? This would force a shift from a capital expenditure-heavy model to an operational expenditure-based model, even in the machinery industry. The Industry 4.0 model will force suppliers to collaborate with customers and competitors to collaborate with peers. It is our task to accompany all parties to take this transformative journey in a step-by-step manner that does not disrupt the current business models unnecessarily.

Where do you see the development in the region?

Roy Chikballapur: We settled in Basel primarily because of its location at the heart of the machine building industry in Europe. In a 300 km radius we have the largest concentration of leading machine building companies in every important industry. What was also a key attraction was the Canton's focus on Industry 4.0. While there are many startup hubs across Europe, they tend to focus on more “sexy” topics like Fintech, Blockchain and AI. Personally, I hope that the region instead takes up something that is more concrete and “real” as its focus area, capitalizing on its strength as a life sciences hub but also as a center of industry and logistics. We would like to see more collaboration among Industry 4.0 startups to integrate each of our products to develop more comprehensive offers for our customer base. We would also like to increase our collaboration with larger industrial companies in the region. I am certain that such a focus on the i4 theme will accelerate innovation and position Basel as a hub for Industry 4.0.

Dominik Trost: As a software company with a standardized product, our outlook is not as much regional, but rather national or defined by language barriers. Looking at the state of AR in Switzerland and Germany, there are indeed more pockets of development here than in other places, mostly in the form of individual startups and university programs. However, AR is still generally viewed as an experimental technology, despite applications being proven viable and beneficial. There is nowhere near as much drive and competition as in the US or East Asia – both a chance and a ticking clock for us.

What are your plans for your company?

Philippe Kapfer: We currently have customers mainly in the Jura and in the French-speaking parts of Switzerland. In addition to our products, I also offer training and audits on information security systems. In the future, I want to put even more capacity into development. We are targeting both the national and international markets with our security software and API. The cybersecurity market is growing by ten percent annually, but not enough people can respond to this development. NextDay.Vision provides the software that satisfies a need and makes it easier for companies to meet high security standards. We want to anchor cybersecurity in the mindset of the industry. This includes enabling connections between customers and manufacturers without sacrificing data security. We are confident that we will continue to grow with our product and vision.

Dominik Trost: At this point, almost anything is possible. We are actively building up our network of distributors and are also looking across the borders, already promoting our solutions in Germany and exploring our options in other countries. It is very likely for foreign competition to enter the European market, which makes it important for us to act quickly and decisively. We have, however, built a competent team and are very confident in the quality our products, so we are looking forward to what the future holds.

Roy Chikballapur: MachIQ has positioned itself as a neutral, brand agnostic player offering software products that connect machine builders and their industrial end-user customers for asset performance management. Machiq’s software creates the dynamics of a “data cooperative” for Industry 4.0. Common data benefits everyone on the system, but is managed securely so that it does not compromise the relationships that companies have built with their suppliers and customers or the competitive dynamics between business peers. Our vision is to become the “Business Operating System” of the Industry 4.0-enabled world. While many companies aren’t thinking about it, the moment we present our vision to them, they immediately get us and they get what we are trying to do. We are experiencing strong growth in our customer base. Consequentially, we are focusing on hiring the right talent and growing the team fast enough right now.

Text: Annett Altvater

report Innovation

University hospital fights multiresistant bacteria

16.11.2018

event BaselArea.swiss

Design as a key value driver

Date: 21.11.2018

Place: Grand Hotel Les Trois Rois, Blumenrain 8, 4001 Basel

report Production Technologies

"I Was Always One of Few Women in the Industry"

27.09.2018

SOLO Swiss in Porrentruy in the canton of Jura has been making industrial furnaces for heat-treating metals since 1924. The family company with a global presence is developing against the backdrop of Industry 4.0 and is struggling to find the qualified workforce which is indispensable for what it does amid the effects of the strong franc and what are sometimes restrictive administrative regulations. Interview with Anne-Sophie Spérison, President and CEO.

BaselArea.swiss: I imagine that Industry 4.0 is a key area of development for you?

Anne-Sophie Spérisen: Absolutely. Industry 4.0 is understood as the collection of all the data available on a machine to convert them into information or “impetus” for other factors included in the ERP (Enterprise Resource Planning) system, for example. It is also about loading and downloading information on preventive or corrective maintenance for a machine. In practice, alerts are triggered if a turbine is gradually approaching the end of its run. This can also be management data which is sent to the control cockpit.

Is there major potential in terms of Industry 4.0 in your company? 

Yes. On our kinds of machines, all the information on each of them could potentially be sent further down the line. Industry 4.0 could also be very useful for maintenance. For example, it would be conceivable to provide our customers with connected glasses so that our technicians could provide instructions from Switzerland while the customer sits in front of their machine in Shanghai, so they can fix the machine themselves. Our objective is to ensure that Industry 4.0 is a real bonus not only for the customer, but also for production, maintenance, monitoring, machine productivity and the management cockpit.

There is sometimes a tendency to bundle everything in with Industry 4.0. But what is it really all about?

It is the extraction and processing of data in a previously unprecedented manner. In Industry 4.0, we are attempting to link new technologies and new processes with exactly this Industry 4.0. At the end of the day, it is almost a question of creating new products and services. That is why we have had an engineer dedicated to this project for two years now, although he is not the only one dealing with it. He needs to have a perfect command of information systems, data processing and emerging technologies (receivers, sensors) – as well as the associated possibilities these offer, since they are evolving all the time. 

What about maintenance?

For us, this is a key issue. In this area, we offer our customers private Internet portals. They can connect remotely from their machines and monitor their production online. We can install sensors all over the machines. They generate relevant information which can then be retransmitted in a form which is coherent, intelligent and comprehensible to the customer as a function of their requirements. Effectively, we need to make all the information available to the customer in the form they want it. For example, a complete log of all maintenance on their furnace.

Still on the subject of Industry 4.0, are you able to find the necessary skills in Jura?

It is not easy. There is a lack of schools providing training. We are primarily looking for IT specialists, specifically specialists in Industry 4.0, but they also need to understand the technology. We need both IT experts and mechanical and electrical engineers. The region here is a centre for micro-technology, which does not tie in with our area of activity.

The future of SOLO lies in…

...perfect mastery of the furnace process, i.e. everything that happens inside the furnace and controls the machine. The customer demands pieces which are perfect after treatment with no reprocessing necessary and a guarantee that they will meet the ever more demanding quality standards of the automotive (CQi9) or aerospace (AMS 2750) industries. The complexity of the parts to be processed, new alloys, new production techniques for metal parts (3D printing), this is our future. It is all about having perfect control of the thermo-chemical processes of our machines. Essentially, it is metallurgy which is controlled by computers.

Will you be able to continue production in Switzerland?

It is a challenge, because we only sell 20% of our machines in Switzerland and we export the rest all over the world because our machines are aimed at niche industries. Added to this is the issue of the strong franc and the problems in finding qualified engineers in Jura, especially as the employment market is so robust. It is a real challenge for us. There is also the difficulty posed by the myriad of standards and regulations, which are coming increasingly complex and onerous at an administrative level. At the same time, however, it is an opportunity for us, as it protects us from competition from low-cost countries who cannot comply with the new and increasingly demanding standards. But remaining competitive at a pricing level is very difficult. That said, the new technologies fortunately give us an opportunity to improve our competitiveness even further.

Are you optimistic?

Yes, I am by nature, even when it’s a daily battle. There are so many parameters which can change very quickly. Luckily, the markets are currently stable, we are seeing good levels of growth from the majority of markets in Europe, Russia and Asia, and we have a range of quality products which are tailored to our niche markets. We also have a fantastic team we can rely on and have some new technical developments in the pipeline. 

What can you say about the Chinese market?

When we started back in the 70s and 80s, we sold furnaces to Chinese purchasing centres. And we also worked with representatives over there. In the 2000s, we entered into a partnership with a local company. Currently, we are working with a production unit in Canton with around one hundred employees. It is a company run by a family who have become our friends. It was necessary, even critical to produce locally for the Chinese market, especially in order to respond to invitations to tender from government companies.

How would you describe the effect of having a woman in charge of the company?

It does not pose any problems personally. I am very much at ease with it. Some people I speak to are put off-balance because a woman is perhaps more direct than a man. We dare to ask questions, we are more stubborn. I grew up being the only girl or one of the few women: there are very few in industry, which I think is regrettable. There are no differences in management styles between men and women. It is more a question of character and sensitivity.

www.solo.swiss

Interview: Didier Walzer

report BaselArea.swiss

Baselland increases startup support

15.11.2018

event ICT

Partner Event: BaselHack meets FinTech Innovators - ideating workshop

Date: 23.11.2018

Place: Auditorium, Wirtschaftswissenschaftliche Fakultät der Universität Basel, Peter Merian-Weg 6, 4052 Basel

report Life Sciences

“Our business is the most beautiful business in the world”

04.09.2018

Giacomo di Nepi has a successful history: A high level executive in big corporations, he transitioned towards biotech, currently as CEO of Polyphor, which, in May 2018, he led to the IPO. We spoke to Giacomo about serving patients, the timing for an IPO and the people needed in a biotech.

BaselArea.swiss: What do you check first these days – your emails or the stock market?

Giacomo di Nepi: Emails and meetings are still more important on a daily basis. Of course I check the stock market but the volatility is such that I stopped to try to interpret the market in the short term. But of course I look at it in its development and my commitment is clear to have the stock appreciating and increasing the value delivered to the shareholders who put their trust and investment in our ideas, technology and team.

You served in big corporations such as McKinsey and Novartis. What made you join a startup like Polyphor?

Sure, I come from multinationals, but I worked elsewhere, too. My last job was with InterMune, a Californian biotech. I started the operations in Europe from zero, from my home. If the weather was nice, we moved our meetings from the dining room into the garden. This grew into an operation of 200 people, bringing the drug to the patients affected by idiopathic pulmonary fibrosis. With a startup, you have the possibility of looking at all the dimensions of a company from a much broader perspective. Therefore, Polyphor was attractive for me, but there were other reasons, too.

Such as…?

… the dramatically fantastic science which certainly is one of the fundamentals. Polyphor is a company that has discovered the first new class of antibiotics against Gram-negative bacteria in the last 50 years. This is radical innovation. Antimicrobial resistance is becoming a huge problem. You have patients that get an infection, then are treated with 20 different drugs and they die nevertheless. This is unacceptable. Pneumonia from Pseudomonas aeruginosa today has a mortality rate of 30 to 40 percent. Also, when a woman has metastatic breast cancer and is in her third line of chemotherapy,  she has very few therapeutic options and her prognosis is devastating. We want to save lives and give more time to patients. This is what for me makes our business the most beautiful business in the world. It is heartbreaking to see these patients.

So you meet with patients?

Sure. Lately, I brought a patient to Polyphor: A fantastic woman with colonization of Pseudomonas took part in the earlier trials. She has great courage and a willingness to fight for life that is really moving and inspiring for all of us. She talked about her experience because I believe that everybody should have a touch of feeling of what we are trying to achieve, such as people not directly involved in development, for example working in units such as in accounting who normally only see the invoices for the trial.

Polyphor underwent a transformation from research to R&D focused biopharma company in the last couple of years. How did the organization digest the change?

When you move from one stage to the next stage, you raise the bar because in development, projects are multi-year, complex projects with big expenditure. It really changes the mindset. Personally, I like change. I am not interested in doing administration. And this particular change was necessary. This being said, we still have a big research operation focused on antibiotics and immuno-oncology, that we want to keep to find and build excellent compounds.

Basel seems to have become a hotspot for antibiotics recently.

Antibiotics have been disregarded by many large companies. But it is like in the Pascal law: if there is an empty space, something will fill it. Smaller, entrepreneurial companies are now taking the lead worldwide – and Basel is one of the key spots. Clearly, we have a very strong science base in Basel. If you want to do R&D, Basel is the best place to do it, in my opinion. And, I would not be surprised if large companies will be back….

Polyphor listed on SIX Swiss Exchange in May 2018 and raised 165 million Swiss francs. Why was an IPO the right option for Polyphor?

If you are lucky, you find a biotech with one product that is one step away from the market. We have two products that are one step away from the market: Our antibiotic Murepavadin has entered phase III while we negotiated a program with the FDA to bring our immune-oncology drug Balixafortide to the market with only one pivotal study. That puts us in a unique position. However, these studies required a lof of capital. Thanks to going public, we have the resources to develop our products and, when successful, bring them to the patients who need them. The IPO was a necessary tool given the stage of the company.

Which conditions had to be met for the IPO?

An IPO is an interesting exercise. It’s a bit like undergoing a complete physical examination. The investors don’t know the company, yet we want them to support our ideas, our vision and our team. That means they need to trust us. To gain that trust you have to be completely transparent and explain in every detail what the company is about, what the opportunities and risks are. In the end, the results were fantastic because we’ve been the largest biotech IPO in Switzerland within the last ten years. And, we’ve been one of the top 3 in Europe in the last three years.

How influential was the timing?

Timing is important, but it is not determining. The first quarter of 2018 was very good for IPOs but the second quarter was not stellar. A dozen IPOs were pulled during that period. It may happen that you have a valid IPO but don’t do it because the timing is wrong. However, you never have a non-valid IPO that you do because the timing is right.

Which reactions did you get towards Polyphor’s IPO?

Internally, we are super happy that we can work towards bringing our drugs to the patients. At the same time, we are very conscious of the responsibility and very committed. Externally, our IPO is a demonstration of the capability Switzerland and particularly the Basel area have in pharmaceuticals. The IPO was a moment of visibility, of public recognition. In a way, an IPO shows how investment-intensive this business is. I hope it’s a good sign for the whole industry that we are capable of starting new companies, making them flourish and bringing new therapies to the patients.

Why did you choose the Swiss Exchange?

We already had quite a large shareholder base in Switzerland, so it was natural to go to the Swiss stock market. We were a known entity. Switzerland is a fantastic market, I am happy with the choice. In fact, I wonder why it is not chosen more often. There are available funds, there are investors that are familiar with pharmaceuticals and that are willing to take the risk.

What are the plans for Polyphor for the next couple of years?

Our vision is clear: We want to become a leader in antibiotics and help fighting and reducing the threat that comes from multi drug resistant pathogens. At the same time we want to advance a new class of immune oncology drugs. We are developing third line therapies for metastatic breast cancer. The women affected by this have very few therapeutic options. However, we believe that the potential of the drug can go beyond this patient population, for example in earlier lines of breast cancer and to other combinations and indications. This would bring us to a much more competitive field.

How do you get there?

We have to make sure that we have the organization and the culture that allow us to perform our studies effectively. We want to make sure that the pieces of the organizational machinery are in the right order and that we have all the competences that we need.

What do you do to achieve this?

I recognize talent as one – if not the – key component of success for a company. Consequently, I dedicate a lot of effort and a lot of commitment to do this task. I interview candidates two or three times, I don’t mind. I also have them interviewed by their future colleagues. When I was at Novartis, I had fantastic experiences with the young high potential. Why? Because they have the brains and the capability. It doesn’t matter if they have little experience because the rest of the organization is stuffed with it. It is different in biotech where you absolutely depend on hiring people with relevant experience since no one else has it in the company.

And how about the cultural changes when transitioning from big pharma into a biotech?

Experience, however, is only part of the story. I met a lot of people who have experience – but are not able of making a photocopy and need three people reporting to them in order to be able to achieve anything. They are not good either. That is why I look for a sort of “schizophrenic profile”: In biotech you need people who have experience, capability and vision while at the same time they need to roll up their sleeves, be practical about their choices and do things on their own.

Interview: Annett Altvater and Stephan Emmerth

report Life Sciences

Van Baerle to benefit from Schweizerhalle location

13.11.2018

event ICT

BaselHack – the second

Date: 24.11.2018

Place: FHNW Academy of Art and Design, Aula, 4142 Münchenstein

report Invest in Basel region

Basel pharma companies invest most in R&D

15.07.2018

The 24 Interpharma companies spent a total of 96 billion Swiss francs on research and development worldwide in 2017. Of this, 7 billion francs were invested in Switzerland. When compared with the sales they generated in Switzerland, the companies’ Swiss research investment was more than twice as high. According to the association, this is a testament to the great significance of Switzerland as a research location and the innovation taking place at these companies.

Investment in research and development has been especially high among companies that have their headquarters in Switzerland, such as Roche and Novartis.

Interpharma highlights the key role the pharma industry in the Swiss export sector plays. The association also notes that more than 86 patents were registered per million employees in pharmaceutical research in Switzerland between 2012 and 2016. This is more than double the number of Denmark and five times as many as in Germany.

Among the Interpharma members are companies such as Novartis, Roche, Pfizer, Astra Zeneca, Sanofi, Lilly, Johnson & Johnson, Bayer or GlaxoSmithKline.

Investments in the future

How committed the life science companies are to Basel is also reflected with regard to their planned investments which is as high as 6 billion Swiss francs. Roche, for instance, is in the process of renewing its Basel and Kaiseraugst sites. By 2023, the company with the long heritage in Basel will have invested 3 billion Swiss francs into their infrastructure. Some buildings are being modernized, while others are rebuilt completely. Bau 1, with 178 meters the tallest building in Switzerland, was opened in 2015 and cost 550 million Swiss Francs.

The remarkable tower that was designed by world-class architects Herzog & de Meuron from Basel provides workspace for approximately 2000 employees. Meanwhile, the big brother is under construction: Bau 2 will be 205 meters high and provide space for approximately 1700 employees. At the Kaiseraugst site, the group constructs an IT hub to gather all IT functions under one roof whilst taking the strategic role of technology and the growing numbers of IT employees into account. Roche will invest more than half a billion Swiss francs in Kaiseraugst.

More investments are under way in Basel:

The Swiss Tropical and Public Health Institute invests 90 millions Swiss francs in their new building in Allschwil, providing 900 workspaces. The new building is due in late 2020.

The Biozentrum of the University of Basel constructs a site for students and researchers, spending 328 million Swiss francs. Further, the University builds a Life Sciences Campus, concentrating different disciplines in one location to foster collaboration. The Department of Biosystems Science and Engineering of the ETH is also part of the project.
The University Hospital of Basel will realize a new building by 2032, costing approximately 1,2 billion Swiss francs. In 2017, the hospital opened new state-of-the-art surgery facilities.

report Life Sciences

T3 Pharmaceuticals wins prestigious startup award

12.11.2018

event Micro, Nano & Materials

Technology Circle „NanoPolymers & Structures“ – hochauflösende Electronenmikroskopie

Date: 27.11.2018

Place: Department of Biosystems Science and Engineering, Misrock-Raum (EG), Mattenstrasse 26, 4058 Basel

report Invest in Basel region

Basel has the biggest economic potential

13.07.2018

Basel has the biggest economic potential in Europe, according to a new study from BAK Economics. The city on the bend of the Rhine ranked particularly well for competitiveness, while Geneva and Zurich also came in the top five.

BAK Economics has published a study on the economic potential of the 65 most important cities and 181 regions in Europe. Its findings revealed that Switzerland’s cities and regions are among the best in the Economic Potential Index.

Basel scooped 116 points to take the top spot. A key factor in its success was its pole position for competitiveness with 124 points. For attractiveness, the city on the bend of the Rhine took third place with 109 points, and for economic performance it ranked equally high with 114 points.

Geneva followed in second place with 115 points among the cities with the highest economic potential. London took third with 113 points and Zurich fourth with 112 points. The city on the Limmat was also named the most attractive of all 65 cities studied.  

On a regional level, Basel was considered part of north-west Switzerland, which ranked fourth with 111 points. For competitiveness, it came second with 117 points, behind the Stockholm capital region with 122 points.

For best regions overall, Zurich was named third with 112 points behind London in second and Stockholm in first place. However, the Swiss regions have the greatest overall economic potential in Europe: the Lake Geneva region ranked sixth, Central Switzerland seventh, and Ticino eighth, with the Swiss regions occupying half of the top ten places.  

report Innovation

Swiss Innovation Forum 2018

08.11.2018

event Innovation

Cyber Security Switzerland 2nd Western European PPP Congress 27. - 30.11.2018

Date: 27.11.2018

Place: Salle de l'Inter Allée des Soupirs 15, 2900 Porrentruy

Cookies

BaselArea.swiss uses cookies to ensure you get the best service on our website.
By continuing to browse the site, you are agreeing to the use of cookies.

Ok